Skip to main content
. Author manuscript; available in PMC: 2020 Nov 1.
Published in final edited form as: Cancer. 2019 Jul 10;125(21):3790–3800. doi: 10.1002/cncr.32340

Table 2:

Overview of most common (≥5% patient in either arm) grade ≥3 toxicities, at least possibly related to treatment

Adverse event, n (%) Arm A
Bevacizumab +
Dasatinib
(N=83)
Arm B
Bevacizumab + Placebo
(N=38)

Hematologic
 Lymphopenia 8 (9.6%) 1 (2.6%)

Non-hematologic
 Hypertension 6 (7.2%) 5 (13.2%)
 Fatigue 10 (12.0%) 0
 Diarrhea 5 (6.0%) 0
 Hypophosphatemia 12 (14.5%) 1 (2.6%)